Drug Profile
Research programme: ophthalmic disease therapies - Summit
Alternative Names: DL 06005; SMT D003; SMT D004Latest Information Update: 14 Mar 2013
Price :
$50
*
At a glance
- Originator Summit plc
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Age-related macular degeneration; Glaucoma
Most Recent Events
- 14 Mar 2013 No development reported - Preclinical for Age-related macular degeneration in United Kingdom (unspecified route)
- 14 Mar 2013 No development reported - Preclinical for Glaucoma in United Kingdom (unspecified route)
- 24 Jun 2009 Preclinical development is ongoing